To systematically review and synthesize evidence on the effectiveness of rituximab, belimumab, and TPO-RAs for refractory ITP in adults with SLE, we conducted a systematic review and meta-analysis of observational studies following a prespecified protocol. This evidence concerns the gene TPO and autoimmune thrombocytopenic purpura.